Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Sep 29:12:114.
doi: 10.1186/1471-2377-12-114.

Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial

Hassan Soleimanpour  1 , Rouzbeh Rajaei Ghafouri, Aliakbar Taheraghdam, Dawood Aghamohammadi, Sohrab Negargar, Samad E J Golzari, Mohsen Abbasnezhad
Affiliations
Randomized Controlled Trial

Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial

Hassan Soleimanpour et al. BMC Neurol. .

Abstract

Background: There are many drugs recommended for pain relief in patients with migraine headache.

Methods: In a prospective double blind randomized clinical trial, 90 patients (age ≥ 18) presenting to Emergency medicine Department with Migraine headache were enrolled in two equal groups. We used intravenous propofol (10 mg every 5-10 minutes to a maximum of 80 mg, slowly) and intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly), in group I and II, respectively. Pain explained by patients, based on VAS (Visual Analogue Scale) was recorded at the time of entrance to ED, and after injection. Data were analyzed by paired samples t test, using SPSS 16. P < 0.05 was considered to be statistically significant.

Results: The mean of reported pain (VAS) was 8 ± 1.52 in propofol group and 8.11 ± 1.31 in dexamethasone group at presenting time (P > 0.05). The VAS in propofol group was obviously decreased to 3.08 ± 1.7, 1.87 ± 1.28 and 1.44 ± 1.63 after 10, 20 and 30 minutes of drug injection, respectively. The VAS in dexamethasone group was 5.13 ± 1.47, 3.73 ± 1.81 and 3.06 ± 2 after 10, 20 and 30 minutes of drug injection, respectively. The mean of reported VAS in propofol group was less than dexamethasone group at the above mentioned times (P < 0.05). The reduction of headache in propofol group, also, was very faster than dexamethasone group (P < 0.05). There were no adverse side effects due to administration of both drugs.

Conclusions: Intravenous propofol is an efficacious and safe treatment for patients presenting with Migraine headache to the emergency department.

Trial registration: Clinical Trials IRCT201008122496N4.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT 2010 Flow Diagram of trial design.
See this image and copyright information in PMC

References

    1. Marx JA, Hockberger R, Walls R. Rosen’s Emergency Medicine: Concepts and Clinical Practice. 7. Elsevir, Philadelphia; 2010. pp. 1356–1359. 2416.
    1. Silberstein S, Merriam G. Sex hormones and headache (Menstural migraine) Neurology. 1999;53:33. - PubMed
    1. Lipton RB, Stewart WF, Diamond S, Diamond M, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646–657. doi: 10.1046/j.1526-4610.2001.041007646.x. - DOI - PubMed
    1. Goadsby PJ, Lipton RB, Ferrari MD. Migraine; current understanding and treatment. N Ergl J Med. 2002;346:257. doi: 10.1056/NEJMra010917. - DOI - PubMed
    1. Kristoffersen ES, Grande RB, Aaseth K, Lundqvist C, Russell MB. Management of primary chronic headache in the general population: the Akershus study of chronic headache. J Headache Pain. 2012;13(2):113–120. doi: 10.1007/s10194-011-0391-8. - DOI - PMC - PubMed

Publication types